Uncategorized
Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction
Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction
The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency’s future regulatory decision-making, analysts say, with implications stretching well beyond one company. Read More